Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
However, we know little about the incidence of MYC/BCL2 double-hit (DH) in BL.
|
26182827 |
2015 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Burkitt lymphoma (BL) is a highly aggressive B-cell lymphoma associated with MYC translocation.
|
30104685 |
2018 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Chromosomal translocations involving MYC at 8q24 are found in Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL (BCLU).
|
22018272 |
2011 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We extended our analysis to 17 MYC-negative high-grade B-cell lymphomas with a similar 11q aberration and showed this aberration to be recurrently associated with morphologic and clinical features of BL.
|
24398325 |
2014 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Here we report that two common mutant MYC alleles derived from human Burkitt's lymphoma uncouple proliferation from apoptosis and, as a result, are more effective than wild-type MYC at promoting B cell lymphomagenesis in mice.
|
16094360 |
2005 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
MYC rearrangement is a recurring genetic abnormality in several aggressive B-cell lymphomas including: Burkitt lymphoma, diffuse large B-cell lymphoma; B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma; rare de novo acute lymphoblastic lymphoma/leukemia, transformed follicular lymphoma, and plasmablastic lymphoma.
|
21490439 |
2011 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Furthermore, MYC-negative tumours had higher levels of miR-29 expression compared with MYC-translocated cases, suggesting that MYC regulates miR-29 in BL tumours.
|
29318382 |
2018 |
Burkitt Lymphoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
A paradigm is the activation of the c-myc gene by chromosomal translocations in Burkitt lymphoma (BL).
|
17211884 |
2007 |
Burkitt Lymphoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Endemic, sporadic and HIV-associated Burkitt lymphoma (BL) all have a B-cell phenotype and a MYC translocation, but a variable association with the Epstein-Barr virus (EBV).
|
19530237 |
2010 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We studied the microRNA profile of MYC translocation-positive and MYC translocation-negative Burkitt lymphoma cases in order to uncover possible differences at the molecular level.
|
26453442 |
2015 |
Burkitt Lymphoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
It has been known for many years that the fundamental transforming event in BL is the translocation of the MYC gene, and the events that bring about this translocation and those that allow cells to survive with the constitutive expression of MYC have been the subject of intense investigation.
|
18042696 |
2007 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Burkitt's lymphoma (BL) is a malignancy of B cells characterized by chromosomal translocations involving the immunoglobulin (Ig) and c-MYC gene loci.
|
12507816 |
2003 |
Burkitt Lymphoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The BL cells showed a ∼90% decrease in MYC transcription upon treatment with JQ1, however, no corresponding reduction was seen in several non-BL cells.
|
24466310 |
2014 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The chromosomal translocation t(8;14)(q24;q32) with juxtaposition of MYC to enhancer elements in the immunoglobulin heavy chain (IGH) gene locus is the genetic hallmark of the majority of Burkitt lymphoma and a subset of Diffuse large B-cell lymphoma patients.
|
23673335 |
2013 |
Burkitt Lymphoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Our analysis provided a novel look on the transition range between FL and DLBCL, on DLBCL with poor prognosis showing expression patterns resembling that of Burkitt's lymphoma and particularly on 'double-hit' MYC and BCL2 transformed lymphomas.
|
31039827 |
2019 |
Burkitt Lymphoma
|
1.000 |
PosttranslationalModification
|
disease |
BEFREE |
We conclude that the two NF-kappa B sites function as positive regulatory regions for the translocated c-myc gene in Burkitt's lymphoma.
|
7969136 |
1994 |
Burkitt Lymphoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Mutations in the exon 1/intron 1 boundary region of the c-myc gene cause an increase in transcriptional elongation in Burkitt lymphoma.
|
8376401 |
1993 |
Burkitt Lymphoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate that the phenotype of B lineage lymphomas induced by MYC dysregulation is highly dependent on cooperativity among the regulatory elements that govern expression of the protooncogene and provide a new system for studying the pathogenesis of BL.
|
11034608 |
2000 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
MYC dysregulation needs other cooperating events for BL development.
|
26887776 |
2016 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Burkitt's lymphoma (BL) is characterized by translocation of the MYC gene to an immunoglobulin locus.
|
20160479 |
2010 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tumours as an "aggressive B-cell non-Hodgkin's lymphoma", characterized by a high degree of proliferation of the malignant cells and deregulation of the c-MYC gene.
|
19670467 |
2009 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We demonstrate that c-Myc proteins harboring a naturally occurring mutation at Thr-58 from BL cell lines have increased stability and are constitutively hyperphosphorylated, which disrupts the in vivo interaction of c-Myc with alpha-tubulin.
|
10866684 |
2000 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
This facilitates survival of eBL tumor cells with the IGH/MYC chromosomal translocation and promotes MYC-induced cell cycle progression, initiating eBL lymphomagenesis.
|
29132323 |
2017 |
Burkitt Lymphoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The regular juxtaposition of the c-myc gene to one of the three immunoglobulin loci in Burkitt's lymphoma, mouse plasmacytoma, and rat immunocytoma is a case in point.
|
3011242 |
1986 |
Burkitt Lymphoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
The t(8;14) breakpoint of the EW 36 undifferentiated lymphoma cell line lies 5' of MYC in a region prone to involvement in endemic Burkitt's lymphomas.
|
3128772 |
1988 |